HomeAI · summaries
Storia in 7 fonti
Eli Lilly Says Retatrutide Shows Cardiovascular, Diabetic Benefits - Eli Lilly (NYSE:LLY)
Eli Lilly reports positive Phase 3 data for retatrutide, showing major weight loss in adults. US regulatory submission is planned for 2027.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people lose nearly 56 pounds on average.
- ·
biopharmadive.com
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on…
